Research programme: cancer immunotherapeutics - ViraxAlternative Names: VIR 501
Latest Information Update: 07 Feb 2011
At a glance
- Originator Virax Holdings
- Developer Australian National University
- Mechanism of Action Immunomodulators; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Prostate cancer
Most Recent Events
- 13 Mar 2009 VIR 501 is available for licensing (http://http://www.virax.com.au)